Approved by the US Food and Drug Administration for the treatment of refractory gout, pegloticase, in combination with immunomodulatory agents, is an area of gout treatment that has shown much promise.
Our featured guest on this episode is Brian LaMoreaux, MD, MS, an investigator on many gout studies, who provides an overview of the notable research in pegloticase treatment in gout, as presented at the American College of Rheumatology (ACR) 2020 annual meeting.
Brian LaMoreaux, MD, MS, is a medical director at Horizon Therapeutics. While holding this position, Dr LaMoreaux also serves as a volunteer clinical rheumatologist with CommunityHealth and as a board member of Mental Health America of the North Shore. He blends science and compassion in his approach to change outcomes for patients living with gout, recognizing that to change the understanding of gout, new research, and continued education is required.
He received a Bachelor’s degree in psychology and also studied epidemiology at Michigan State University before completing his MD from Wayne State University School of Medicine in Michigan.
Dr LaMoreaux was a rheumatologist at the Ohio State University College of Medicine prior to assuming his current role at Horizon Therapeutics.